Rhone-Poulenc Rorer Targets September Launch For Synercid In U.K.
Executive Summary
Rhone-Poulenc Rorer's injectable streptogramin antibiotic Synercid (quinupristin/dalfopristin) is expected to be launched in the U.K. by October, following approval by the Medicines Control Agency on July 29.
You may also be interested in...
P&U Zyvox Surveillance Program To Provide Resistance Data To Physicians
Pharmacia & Upjohn is developing a resistance surveillance program for physicians in conjunction with the future launch of its antimicrobial Zyvox.
RPR Contract With Catalytica Gives Backup Synercid Production
Rhone-Poulenc Rorer's licensing of Synercid production to Catalytica will provide the company with a backup facility for the production of the antibiotic.
Cubist Daptomycin VRE Pivotal Trial May Include Synercid Comparison
Pivotal trials for Cubist's daptomycin antibiotic against vancomycin-resistant Enterococcus are expected to include a comparative arm with Rhone-Poulenc Rorer's Synercid (quinupristin/dalfopristin).